Valuation: Patrys Limited

Market Cap 1.57Cr 1.09Cr 97.23L 90.12L 81.99L 1.55Cr 103.81Cr 11Cr 4.25Cr 54Cr 4.11Cr 4.02Cr 172.69Cr P/E 2025
-0.68x
P/E 2026 -4.22x
Enterprise Value 1.24Cr 86L 76.45L 70.86L 64.47L 1.22Cr 82Cr 8.52Cr 3.34Cr 43Cr 3.23Cr 3.16Cr 135.78Cr EV / Sales 2025
1.96x
EV / Sales 2026 2,223x
Free-Float
70.71%
Yield 2025 *
-
Yield 2026 -
1 day-6.90%
1 week-10.00%
Current month-12.90%
1 month-20.59%
3 months-28.95%
6 months+3.85%
Current year-3.57%
1 week 0.03
Extreme 0.027
0.03
1 month 0.03
Extreme 0.027
0.03
Current year 0.02
Extreme 0.025
0.05
1 year 0.02
Extreme 0.025
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.55
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

3,96,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

13,37,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-10.00%-10.00%-71.87% 1.09Cr
-6.60%-8.56%+42.79%+64.16% 6.5TCr
-4.09%-0.11%+2.31%+54.81% 5.12TCr
+0.03%+5.56%+10.18%+41.75% 5.12TCr
-1.53%+2.70%+29.72%+34.13% 4.39TCr
-1.34%+4.12%+16.05%+112.18% 4.2TCr
-5.97%-6.22%+258.21%+421.57% 3.81TCr
+6.53%+8.02%+15.74%+53.94% 3.32TCr
-0.90%-10.49%+31.48%-1.63% 2.52TCr
-2.76%-9.54%-16.53%-9.55% 2.2TCr
Average -2.35%-2.50%+37.99%+69.95% 3.72TCr
Weighted average by Cap. -2.30%-1.21%+43.56%+88.57%

Financials

2025 2026
Net sales 8L 6L 5L 5L 4L 8L 5.47Cr 57.09L 22.38L 2.86Cr 21.64L 21.18L 9.1Cr 8.98T 6.25T 5.56T 5.15T 4.69T 8.84T 6L 61.91T 24.27T 3L 23.46T 22.96T 10L
Net income -30.13L -20.97L -18.64L -17.27L -15.72L -29.66L -20Cr -2.08Cr -81.41L -10Cr -78.69L -77.01L -33Cr -34.15L -23.76L -21.12L -19.58L -17.81L -33.62L -23Cr -2.35Cr -92.28L -12Cr -89.19L -87.29L -38Cr
Net Debt -7L -5L -5L -4L -4L -7L -4.9Cr -51.16L -20.06L -2.56Cr -19.39L -18.97L -8.16Cr -33.6L -23.38L -20.78L -19.26L -17.53L -33.07L -22Cr -2.32Cr -90.78L -12Cr -87.74L -85.88L -37Cr
Projected Income Statement - Annual - Patrys Limited
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
16/26/16 A$0.0270 -6.90% 5,53,613
15/26/15 A$0.0290 -3.33% 34,714
14/26/14 A$0.0300 0.00% 16,667
13/26/13 A$0.0300 0.00% 1,37,470
12/26/12 A$0.0300 0.00% 13,94,568